Diabetes · Phase 3
AWARD-PEDS: diabetes in youths
What was tested?
Dulaglutide versus placebo in youths with type 2 diabetes, followed by an open-label extension. ↗
Registered primary question: Change in HbA1c at week 26, pooling the dulaglutide groups. ↗
What the reviewed report found
Journal year 2022 · Article summary reviewed 2026-09-15
Glycated hemoglobin decreased in the dulaglutide groups and increased with placebo. BMI change did not differ between groups; gastrointestinal adverse events were more frequent with dulaglutide.↗
Keep in context: The placebo-controlled comparison lasted 26 weeks; participants originally receiving placebo then received dulaglutide. The later extension is not another concurrent placebo comparison. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 154 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Double
- Design
- Parallel
- Eligible ages
- 10 Years to 17 Years
- Registry results
- Posted in this snapshot
Registry source ↗ · Updated 2022-07-01; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
AWARD-PEDS: glycemic control in youths
- Design in the report
- A blinded randomized placebo-controlled study evaluated a 26-week primary endpoint, followed by an open-label extension.↗
- Participants in the report
- The trial randomized 154 participants aged 10 to under 18 with type 2 diabetes.↗
- Limitations
- The primary outcome was glycemic control, not cardiovascular events or long-term complications. The short blinded period limits longer-term conclusions; PubMed links subsequent correspondence.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes ↗
Protocol identifier: 14171. Sponsor: Eli Lilly and Company.
Retrieved 2026-09-20; SHA-256 66bf333495bdabbcc10638f4dbbcb94331c6ffd73afcbef09a45a2ebc9dbaac6.
PMID 35658022
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. ↗
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 35658022. SHA-256 f2177628b98083064df17512c3dd229b760887c00cc64c4cfa4fc4e49523b12a.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 dc1082dfd33187fb63389cc88f10e6d5687b40ee291e3ef7c129e6cfe27f6246.